Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Captrust Financial Advisors

Captrust Financial Advisors increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,680,699 shares of the biopharmaceutical company’s stock after purchasing an additional 49,776 shares during the quarter. Captrust Financial Advisors owned 0.13% of Gilead Sciences worth $140,910,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of GILD. Atria Investments Inc increased its stake in shares of Gilead Sciences by 16.2% in the first quarter. Atria Investments Inc now owns 89,515 shares of the biopharmaceutical company’s stock worth $6,557,000 after acquiring an additional 12,507 shares during the period. Cetera Investment Advisers raised its stake in shares of Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after buying an additional 119,909 shares during the last quarter. Cetera Advisors LLC lifted its holdings in shares of Gilead Sciences by 167.2% in the 1st quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock valued at $6,064,000 after buying an additional 51,801 shares during the period. Railway Pension Investments Ltd lifted its holdings in shares of Gilead Sciences by 0.3% in the 1st quarter. Railway Pension Investments Ltd now owns 1,563,965 shares of the biopharmaceutical company’s stock valued at $114,560,000 after buying an additional 4,800 shares during the period. Finally, IMS Capital Management boosted its stake in shares of Gilead Sciences by 34.8% in the first quarter. IMS Capital Management now owns 6,623 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 1,710 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wolfe Research began coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $74.00 to $96.00 in a report on Monday, October 21st. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Finally, Barclays increased their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.41.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $92.41 on Friday. The firm has a market capitalization of $115.17 billion, a PE ratio of 1,026.78, a price-to-earnings-growth ratio of 2.87 and a beta of 0.17. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business’s fifty day moving average price is $88.08 and its 200 day moving average price is $77.52. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 1.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,735 shares of company stock worth $5,589,030 in the last 90 days. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.